Global Incretin Mimetics Market, By Indication (Diabetes, Others), Drugs (Exenatide, Liraglutide, Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Others), Route of Administration (Oral, parenteral, Others), Application (Solid Tumors, Blood-related Tumor), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Incretin Mimetics Market Analysis and Size
The global incretin mimetics market is expected to witness significant growth during the forecast period. Growing cases of type 2 diabetes mellitus drive the incretin mimetics market. Due to increased inherited disorder & adaptation of unhealthy lifestyle, which causes type 2 diabetes also boost up the incretin mimetics market growth. The major market players in the neuraminidase inhibitors market are focusing on launching new drugs in the market, which is expected to grow in the market in the forecast period. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global incretin mimetics market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Incretin mimetics are the agents are used to treat type 2 diabetes. They act like incretin hormones such as GLP-1 (glucagon-like peptide-1). They bind to the GLP-1 receptors and stimulate glucose dependent insulin release, therefore acting like antidiabetic agents. Incretin mimetics also inhibit glucagon secretion, suppress appetite, slow gastric emptying time, and prevent a steep rise in post-prandial blood glucose levels.
Incretin Mimetics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Diabetes, Others), Drugs (Exenatide, Liraglutide, Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Others), Route of Administration (Oral, parenteral, Others), Application (Solid Tumors, Blood-related Tumor), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)
|
|
Market Opportunities
|
|
Global Incretin Mimetics Market Dynamics
Drivers
- Rising Incidence of Diabetes
The adult diabetes population in 2021 was approximately 537 million, and this number will rise to 643 million in 2030. There are several factors such as obesity, unhealthy diet, and physical inactivity because of which the rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase. Thus, this boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most of the products are available in capsule form and tablet form and it is a very feasible route of administration.
Opportunities
- Technological Development
Several technological developments in the field are constantly improving for the patients' better improvement. Major market players primarily focus on upgrading the drugs, which works as an opportunity for the market to grow. In addition, improving treatment, better equipment for disease detection, and hospital facilities are expected to boost the market demand. Thus, all these factors enhance the market expansion.
- Increasing Demand for Retail Pharmacies
The rise in the number of renal drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Renal Drugs
The side effects associated with these agents could curb the growth of the global incretin mimetics market over a forecast period. Effects such as vomiting, nausea, pain, and several others, can hamper the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global incretin mimetics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global incretin mimetics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Incretin Mimetics Market Scope
The global incretin mimetics market is segmented on the basis of indication, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Diabetes
- Others
Drugs
- Exenatide
- Liraglutide
- Sitagliptin
- Saxagliptin
- Alogliptin
- Linagliptin
- Others
Application
- Solid Tumors
- Blood-related Tumor
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Incretin Mimetics Market Regional Analysis/Insights
The global incretin mimetics market is analysed and market size insights and trends are provided by indication, drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global incretin mimetics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for global incretin mimetics market throughout the forecasted period due to increased government awareness programs and number of generic drugs.
North America dominates the market due to the presence of key manufacture of the product, high research and development, healthcare expenditure, and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Incretin Mimetics Market Share Analysis
The global incretin mimetics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global incretin mimetics market.
Key players operating in the global incretin mimetics market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
SKU-